VA
FOLD

Vident Advisory’s Amicus Therapeutics FOLD Stock Holding History

Vident Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,391
Closed -$305K – 1876
2025
Q4 		$305K Sell
21,391
-3,574
-14% -$35.1K ﹤0.01% 1369
2025
Q3 		$197K Buy
24,965
+2,278
+10% +$16.2K ﹤0.01% 1562
2025
Q2 		$130K Buy
22,687
+10,230
+82% +$66K ﹤0.01% 1549
2025
Q1 		$102K Buy
+12,457
New +$115K ﹤0.01% 1506
2024
Q4 		– Sell
-130,108
Closed -$1.39M – 1483
2024
Q3 		$1.39M Buy
130,108
+21,229
+19% +$231K 0.04% 520
2024
Q2 		$1.08M Buy
108,879
+28,842
+36% +$296K 0.03% 569
2024
Q1 		$943K Buy
80,037
+13,202
+20% +$169K 0.02% 594
2023
Q4 		$948K Buy
66,835
+50,741
+315% +$576K 0.02% 573
2023
Q3 		$196K Buy
+16,094
New +$208K 0.01% 1123

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vident Advisory's FOLD Position: Q1 2026 in Review

Vident Advisory sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 21,391 shares — an estimated $305K sold.

Vident Advisory first reported a position in FOLD in Q3 2023 and held it in 9 quarters. The position peaked at $1.39M in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Vident Advisory reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vident Advisory sold 21,391 Amicus Therapeutics shares in Q1 2026, an estimated $305K.
  • Vident Advisory first reported a position in Amicus Therapeutics in Q3 2023 and held it in 9 quarters.
  • Vident Advisory's Amicus Therapeutics position peaked at $1.39M in Q3 2024.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.